Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer

Journal of Clinical Oncology

Volumn 32, Issue 28, 2014, Pages 3111-3117

  Tworoger, Shelley S ^a,b   Zhang, Xuehong ^a,b   Eliassen, A Heather ^a,b   Qian, Jing ^c   Colditz, Graham A ^d   Willett, Walter C ^a,b   Rosner, Bernard A ^a,b   Kraft, Peter ^b   Hankinson, Susan E ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRONE; ESTRONE SULFATE; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; HORMONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSAL BREAST CANCER; POSTMENOPAUSE; TUMOR INVASION; AGED; ANALOGS AND DERIVATIVES; BLOOD; BREAST NEOPLASMS; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

AGED; BREAST NEOPLASMS; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; ESTRONE; FEMALE; HORMONES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MODELS, STATISTICAL; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLACTIN; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 84907584496     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.1068     Document Type: Article

References (52)

1. Meads C, Ahmed I, Riley RD: A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat 132:365-377, 2012
2. Gail MH, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886, 1989
3. Rockhill B, Byrne C, Rosner B, et al: Breast cancer risk prediction with a log-incidence model: Evaluation of accuracy. J Clin Epidemiol 56:856-861, 2003
4. Rosner B, Colditz GA: Age at menopause: Imputing age at menopause for women with a hysterectomy with application to risk of postmenopausal breast cancer. Ann Epidemiol 21:450-460, 2011
5. Baglietto L, Severi G, English DR, et al: Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev 19:492-502, 2010
6. Falk RT, Brinton LA, Dorgan JF, et al: Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: A nested case-control study. Breast Cancer Res 15:R34, 2013
7. Kaaks R, Rinaldi S, Key TJ, et al: Postmenopausal serum androgens, oestrogens and breast cancer risk: The European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12: 1071-1082, 2005
8. Key T, Appleby P, Barnes I, et al: Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 94:606-616, 2002
9. Tworoger SS, Eliassen AH, Zhang X, et al: A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 73:4810-4819, 2013
10. Yoshimoto N, Nishiyama T, Toyama T, et al: Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women. Cancer Sci 102:2065-2072, 2011
11. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, et al: Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: Long-term results of a prospective study. Br J Cancer 90:153-159, 2004
12. Zhang X, Tworoger SS, Eliassen AH, et al: Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 137:883-892, 2013
13. Tworoger SS, Rosner BA, Willett WC, et al: The combined influence of multiple sex and growth hormones on risk of postmenopausal breast cancer: A nested case-control study. Breast Cancer Res 13:R99, 2011
14. Darabi H, Czene K, Zhao W, et al: Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res 14:R25, 2012
15. Hü sing A, Canzian F, Beckmann L, et al: Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. J Med Genet 49:601-608, 2012
16. Mealiffe ME, Stokowski RP, Rhees BK, et al: Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst 102:1618-1627, 2010
17. Tamimi RM, Rosner B, Colditz GA: Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion. Cancer 116:4944-4953, 2010
18. Tice JA, Cummings SR, Smith-Bindman R, et al: Using clinical factors and mammographic breast density to estimate breast cancer risk: Development and validation of a new predictive model. Ann Intern Med 148:337-347, 2008
19. Pharoah PD, Antoniou AC, Easton DF, et al: Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358:2796-2803, 2008
20. Wacholder S, Hartge P, Prentice R, et al: Performance of common genetic variants in breast-cancer risk models. N Engl J Med 362:986-993, 2010
21. Rosner BA, Colditz GA, Hankinson SE, et al: Validation of Rosner-Colditz breast cancer incidence model using an independent data set, the California Teachers Study. Breast Cancer Res Treat 142:187-202, 2013
22. Costantino JP, Gail MH, Pee D, et al: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541-1548, 1999
23. Colditz GA, Rosner B: Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses'Health Study. Am J Epidemiol 152:950-964, 2000
24. Hankinson SE, Willett WC, Manson JE, et al: Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87:1297-1302, 1995
25. Rockhill B, Spiegelman D, Byrne C, et al: Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358-366, 2001
26. Franz C, Watson D, Longcope C: Estrone sulfate and dehydroepiandrosterone sulfate concentrations in normal subjects and men with cirrhosis. Steroids 34:563-573, 1979
27. Rosner B: Percentage points for a generalized ESD many-outlier procedure. Technometrics 25: 165-172, 1983
28. Hornung RW, Reed LD: Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg 5:46-51, 1990
29. Tworoger SS, Eliassen AH, Rosner B, et al: Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64:6814-6819, 2004
30. Rosner B, Cook N, Portman R, et al: Determination of blood pressure percentiles in normalweight children: Some methodological issues. Am J Epidemiol 167:653-666, 2008
31. Tworoger SS, Missmer SA, Barbieri RL, et al: Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J Natl Cancer Inst 97:595-602, 2005
32. Janes H, Pepe MS: Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: An old concept in a new setting. Am J Epidemiol 168:89-97, 2008
33. Rosner B, Glynn RJ: Power and sample size estimation for the Wilcoxon rank sum test with application to comparisons of C statistics from alternative prediction models. Biometrics 65:188-197, 2009
34. Rosner B, Colditz GA, Iglehart JD, et al: Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: Prospective data from the Nurses'Health Study. Breast Cancer Res 10:R55, 2008
35. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
36. King MC, Wieand S, Hale K, et al: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251-2256, 2001
37. Powles TJ, Ashley S, Tidy A, et al: Twentyyear follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283-290, 2007
38. Xie B, Tsao SW, Wong YC: Induction of high incidence of mammary tumour in female Noble rats with a combination of 17beta-oestradiol and testosterone. Carcinogenesis 20:1069-1078, 1999
39. Liao DZ, Pantazis CG, Hou X, et al: Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: Probable mediation by steroid receptors. Carcinogenesis 19: 2173-2180, 1998
40. Gutzman JH, Miller KK, Schuler LA: Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol 88:69-77, 2004
41. Clevenger CV, Furth PA, Hankinson SE, et al: The role of prolactin in mammary carcinoma. Endocr Rev 24:1-27, 2003
42. Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis 21:427-433, 2000
43. Liao DJ, Dickson RB: Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 80: 175-189, 2002
44. Tworoger SS, Hankinson SE: Prolactin and breast cancer risk. Cancer Lett 243:160-169, 2006
45. Schoemaker MJ, Folkerd EJ, Jones ME, et al: Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: Results from the Breakthrough Generations Study. Br J Cancer 110:1898-1907, 2014
46. Tamimi RM, Byrne C, Colditz GA, et al: Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 99:1178-1187, 2007
47. Varghese JS, Smith PL, Folkerd E, et al: The heritability of mammographic breast density and circulating sex-hormone levels: Two independent breast cancer risk factors. Cancer Epidemiol Biomarkers Prev 21:2167-2175, 2012
48. Baer HJ, Tworoger SS, Hankinson SE, et al: Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol 171:1183-1194, 2010
49. Eliassen AH, Hankinson SE, Rosner B, et al: Physical activity and risk of breast cancer among postmenopausal women. Arch Intern Med 170: 1758-1764, 2010
50. Gail MH: Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst 101:959-963, 2009
51. Rosner W, Hankinson SE, Sluss PM, et al: Challenges to the measurement of estradiol: An Endocrine Society position statement. J Clin Endocrinol Metab 98:1376-1387, 2013
52. Rosner W, Vesper H: Toward excellence in testosterone testing: A consensus statement. J Clin Endocrinol Metab 95:4542-4548, 2010